A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

A new report says the withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV.